The simultaneous administration of the DNA topoisomerase II inhibitor etoposide (0.15 mM) and 1,25-dihydroxyvitamin D 3 (VD 3 ) (10 nM) synergistically induced the differentiation of HL-60 human promyelocytic leukemia cells. Similar results were obtained using U-937 human promonocytic cells, or the topoisomerase II inhibitors doxorubicin (15 nM) and mitoxantrone (2.5 nM). When sequential treatments were used, pre-incubation with VD 3 had little effect on the subsequent action of etoposide, while pre-incubation with etoposide greatly potentiated the subsequent action of VD 3 . In addition, etoposide treatment stimulated VD 3 binding activity and increased VD 3 receptor mRNA and protein levels. The increase in hormone receptor expression may explain, at least in part, the capacity of topoisomerase inhibitors to potentiate the differentiation inducing activity of VD 3. (Mol Cell Biochem 208: 157-162, 2000) 
Introduction
It is known that 1,25-dihydroxyvitamin D 3 (VD 3 ) is the major biologically active metabolite of vitamin D 3 and its principal mediator in bone and mineral metabolism [1, 2] . In addition, VD 3 has other activities not directly related to mineral homeostasis, such as the capacity to induce differentiation of mouse and human myeloid cell lines [3] [4] [5] , and to prolong the survival of mice inoculated with myeloid leukemia cells [6] . These observations suggested that VD 3 could be useful in the treatment of human malignancies, as an inducer of terminal cell differentiation. However, the clinical application of this agent is severely hampered because of its hypercalcemic effects. Possible alternatives to circumvent this problem are the generation of VD 3 analogs without calcium mobilizing action, or the potentiation of VD 3 activity by combination with other appropriate drugs.
Etoposide (VP-16) is a cytotoxic, antitumour DNA topoisomerase II inhibitor which, when used at high concentrations (12 mM), rapidly causes death of myeloid leukemia cells by apoptosis [7, 8] . However, when used at low concentrations (0.15 mM or less), it may induce differentiation [9] and increase the differentiation-inducing activity of other agents [10, 11] . In the present work, we examine the capacity etoposide and other topoisomerase II inhibitors to potentiate the action of VD 3 human myeloid leukemia cells.
Materials and methods

Cell culture and drug treatment
HL-60 human promyelocytic and U-937 human promonocytic leukemia cells were grown in RPMI 1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum and 0.2% sodium bicarbonate in humidified 5% CO 2 atmosphere at 37°C. Cells were seeded at concentrations of 1-2 × 10 5 cells/ml and maintained in continuous logarithmic growth by passing them every 2-3 days. Etoposide, doxorubicin and 12-0-tetradecanoyl-phorbol-13 acetate (TPA) were obtained from Sigma Química, Madrid, Spain. VD 3 and mitoxantrone were a generous gift of Dr. M. Uskokovic (Hoffman-LaRoche, Nutley, NJ, USA) and American Cyanamid (Pearl River, NY, USA), respectively. Etoposide and TPA were dissolved in dimethylsulfoxide (DMSO) at 20 and 1.5 mM, respectively, Mitoxantrone and doxorubicin were prepared at a concentration of 1 mM in distilled water prior to each experiment and VD 3 in absolute ethanol at 10 mM. All these stock solutions were stored at -20°C. At the final concentrations used the solvents were without significant effects on cell growth and differentiation. For experiments, the cells were seeded at 2 × 10 5 cells/ml in a mixture of old and fresh medium (1/3, v/v). To prevent long-term cultures from reaching plateau densities, at the 2nd day of treatment both untreated and drug-treated cultures were supplemented with an equal volume of fresh medium, containing the drug when required. Cell growth was checked using an hemocytometer. Cell death with characteristics of apoptosis was examined by staining with 4,6-diamino-2-phenolindole (DAPI) and examination of chromatin structure by fluorescence microscopy, as previously described [8] .
Measurement of differentiation markers
To measure nitroblue tetrazolium (NBT) reduction, 10 6 cells were incubated for 30 min at 37°C in 1 ml phosphate buffered saline (PBS) containing 0.1% NBT (Sigma) and 150 nM TPA, after which 0.2 ml of 5 N HCl was added and the cells left for 1 h at room temperature. Upon centrifugation, the formazan precipitates were dissolved in 1 ml DMSO and the absorbance measured by spectrometry at 560 nM α-Napthyl acetate (nonspecific) esterase was measured using a research kit from Sigma, following the procedure described by the manufacturer.
VD 3 binding assays
Samples of 3 × 10 6 cells were incubated for 1 h at 37°C with 0.3 nM 3 H-labelled VD 3 (NEN Life Science Products, Brussels, Belgium), either in the absence or the presence of 500 nM unlabelled hormone. The cells were then washed and resuspended in ice cold STM buffer (50 mM Tris, pH 7.4, containing 250 mM sucrose and 5 mM MgSO 4 ) for 15 min, after which Triton X-100 was added to a final concentration of 1% (v/v), and the incubation followed for 15 min at 4°C with overhead tumbling. The nuclei were collected by centrifugation at 4°C and prepared for radioactivity counting. The results were calculated as specific binding, which was obtained by subtracting the counts (non-specific binding) obtained with cells incubated with unlabelled VD 3 from the counts obtained with cells incubated in the absence of unlabelled hormone.
Immunoblot assays
Nuclear protein extracts were prepared according to the method of Schreibert et al. [12] . Protein concentrations were determined according to the Bradford's method [13] . Aliquots of 250 mg proteins were separated by SDS-PAGE in 10% polyacrylamide slab minigels and blotted to PVDF membranes, essentially as previously described [14] . After blocking with 3% non-fat milk, the membranes were incubated for 2 h at room temperature with an anti-VD receptor monoclonal antibody (clone 9A7, Alexis Corporation, Läufelfingen, Switzerland), then extensively washed and incubated again for 1 h with an anti-rat horseradish peroxidase-conjugated antibody (Chemicon International Inc., Temecula, CA, USA). The membranes were developed using an ECL Plus Western blotting detection system (Amersham Ibérica, Madrid, Spain), following the procedure indicated by the manufacturer.
RNA blot assays
The whole procedure was as previously described [15] . The cDNAs used as probes were the 2 kb human VD 3 receptorspecific EcoRI fragment of pSG-hVDR plasmid [16] and the 0.66-kb mouse β-actin-specific KpnI-BglII fragment of pAL41 plasmid [17] .
Statistical analysis
The results are presented as means ± S.E.M. of the number of experiments indicated. Statistical significance was determined by ANOVA followed by Dunnet's post-test. Differences were considered statistically significant when p < 0.05.
Results
Cell differentiation and death
Firstly, we measured the capacity of 0.15 mM etoposide and 10 nM VD 3 to cause HL-60 cell differentiation and death, when applied alone or in combination. These concentrations were adopted on the ground of our previous studies on myeloid cell differentiation [9, 18] . The results are indicated in Fig. 1 . Both agents stimulated NBT reduction, which measures myeloid differentiation, as well as α-napthyl acetate esterase (NSE) staining, which specifically measures differentiation along the monocyte pathway. The expression of these differentiation markers was much higher when etoposide and VD 3 were applied together, revealing the existence of a synergistic action. At the low concentration used, etoposide was only slightly toxic (about a 20% apoptotic cells at the 3rd day of treatment). VD 3 alone did not cause cell death, and even reduced the apoptosis produced by etoposide. Similar results were obtained using U-937 promonocytic cells ( Fig. 2A ) or when doxorubicin (15 nM) and mitoxantrone (2.5 nM) were used in place of etoposide (Fig. 2B) , indicating that the synergic effect may be extended to other myeloid cells types and topoisomerase II inhibitors.
Then, we wanted to analyze the capacity of etoposide and VD 3 to induce differentiation when these agents were sequentially applied. With this aim, cells were pre-treated for 24 h with VD 3 alone and then treated for 48 and 72 h with etoposide alone; or pre-treated for 24 h with etoposide alone and then treated for 48 and 72 h with VD 3 alone. The results indicated that pre-treatment with VD 3 only marginally potentiated the expression of differentiation markers caused by etoposide treatment (Fig. 3A) . In spite of it, under these conditions VD 3 was still able to reduce the apoptotic action of etoposide to similar values as in Fig. 1 (results not shown) . By contrast, pre-treatment with etoposide greatly potentiated the expression of differentiation markers caused by VD 3 treatment (Fig. 3B) . Under these conditions, none of the treatments produced significant apoptosis (all values were below 8% at 72 h).
VD 3 binding and VD 3 receptor expression
Since etoposide potentiated the action of VD 3 , we wanted to know whether the topoisomerase inhibitor was able to stimulate VD 3 binding activity. The results in Fig. 4A indicate that, in fact, etoposide stimulated VD 3 binding in both HL-60 and U-937 cells, reaching approximately a 1-fold increase at 72 h of treatment. Such an increase in binding was probably due to the stimulation of VD 3 receptor expression, since etoposide also increased the VD 3 receptor protein level, as determined by immunoblot assays (Fig. 4B) , and mRNA level, as determined by Northern blot assays (Fig. 5) .
Discussion
Earlier observations indicated that cytostatic/cytotoxic drugs may synergistically cooperate with physiological inducers to cause myeloid cell differentiation [10, 11, 19, 20] . These observations were confirmed here by the simultaneous application of topoisomerase II inhibitors (etoposide, doxorubicin and mitoxantrone) and VD 3 to HL-60 or U-937 myeloid cells. However, there is not coincidence regarding the most appropriate combinations, when those agents are sequentially applied. For instance, it was indicated that pretreatment with etoposide potentiated the differentiationinducing activity of retinoic acid in HL-60 cells [11] . By contrast, a short pre-treatment with retinoic acid sensitized NB4 cells to differentiate in response to hexamethylene bisacetamide or butyrate, while the opposite sequence of treatments was ineffective [19] . Our present results demonstrated the existence of synergism only when etoposide was Fig. 1 . Induction of HL-60 cell differentiation and death by etoposide and VD 3 . The histograms show the reduction of NBT to formazan, as determined spectrometrically; the frequency of cells stained with α-napthyl acetate esterase (NSE); and the frequency of apoptotic cells, as revealed by chromatin fragmentation, in cells treated for 48 and 72 h with 0.15 mM etoposide and 10 nM VD 3 , either alone or in combination. The results are the mean ± S.E.M. of at least 3 independent experiments. The difference was significant at p < 0.05. applied prior to VD 3 but not following the opposite sequence, which may be explained by the capacity of the topoisomerase inhibitor to potentiate the hormone activity. This suggests that administration of a low dose of etoposide together with (or prior to) VD 3 may be an appropriate combination to be used in differentiation therapies with myeloid leukemia cells. For instance, such a combination might allow to decrease the dosage of VD 3 , hence reducing its hypercalcemic effect.
In addition, our results demonstrate that etoposide stimulates VD 3 binding activity as well as VD 3 receptor gene expression. Hence, the capacity of the topoisomerase inhibitor to potentiate the action of VD 3 may be the result, at least in part, of an increase in hormone receptor number. This does not exclude additional explanations, such as the stimulation of other genes and/or intracellular signals which could be important for differentiation. Actually, we earlier demonstrated that low concentrations of etoposide stimulated protein kinase C activity, c-jun and c-fos expression and AP-1 binding activity [21] and these events are known to be involved in the regulation of myeloid cell differentiation [22, 23] . This possibility is under investigation. 
